Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

The use of novel B-cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B-cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia. Ibrutinib, the fir...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Haematologica (Roma) Ročník 102; číslo 10; s. 1629 - 1639
Hlavní autoři:	de Weerdt, Iris, Koopmans, Suzanne M., Kater, Arnon P., van Gelder, Michel
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Italy Ferrata Storti Foundation 01.10.2017
Témata:	Agammaglobulinaemia Tyrosine Kinase Antineoplastic Agents - adverse effects Disease Management Drug Interactions Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - therapy Humans Incidence Leukemia, Lymphocytic, Chronic, B-Cell - complications Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphoma, B-Cell - complications Lymphoma, B-Cell - drug therapy Protein Kinase Inhibitors - adverse effects Protein-Tyrosine Kinases - antagonists & inhibitors Purines - administration & dosage Purines - adverse effects Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrimidines - administration & dosage Pyrimidines - adverse effects Quinazolinones - administration & dosage Quinazolinones - adverse effects Review Severity of Illness Index
ISSN:	0390-6078, 1592-8721, 1592-8721
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The use of novel B-cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B-cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia. Ibrutinib, the first-in-class inhibitor of Bruton tyrosine kinase, and idelalisib, the first-in-class inhibitor of phosphatidylinositol 3-kinase , have recently been approved for the treatment of several indolent B-cell malignancies. These drugs are especially being used for previously unmet needs, i.e., for patients with relapsed or refractory disease, high-risk cytogenetic or molecular abnormalities, or with comorbidities. Treatment with ibrutinib and idelalisib is generally well tolerated, even by elderly patients. However, the use of these drugs may come with toxicities that are distinct from the side effects of immunochemotherapy. In this review we discuss the most commonly reported and/or most clinically relevant adverse events associated with these B-cell receptor inhibitors, with special emphasis on recommendations for their management.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0390-6078 1592-8721 1592-8721
DOI:	10.3324/haematol.2017.164103